{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:45:16Z","timestamp":1761237916282},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5 and 6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/fbp.0b013e3283566a8c","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T12:49:52Z","timestamp":1340887792000},"page":"537-550","source":"Crossref","is-referenced-by-count":21,"title":["Reports of the death of CB1 antagonists have been greatly exaggerated"],"prefix":"10.1097","volume":"23","author":[{"given":"Peter J.","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00008877-201209000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T01:42:11Z","timestamp":1618364531000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008877-201209000-00009"}},"subtitle":["recent preclinical findings predict improved safety in the treatment of obesity"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":0,"journal-issue":{"issue":"5 and 6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0b013e3283566a8c","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}